Henry Schein Reports Record Fourth Quarter And Full Year 2018 Financial Results

Go back to Henry Schein Reports Record Fourth Quarter And Full Year 2018 Financial Results

Henry Schein (HSIC) PT Lowered to $65 at Stifel

February 21, 2019 9:11 AM EST

Stifel analyst Jonathan Block lowered the price target on Henry Schein (NASDAQ: HSIC) to $65.00 (from $85.00) while maintaining a Hold rating following the company's 4Q. Results were lighter than expected. Adjusted internal sales growth of +2.6% was below +4.8% estimates, and the 4Q18 two-year stacked adjusted... More

Henry Schein (HSIC) PT Lowered to $59 at Baird

February 21, 2019 8:54 AM EST

Baird analyst Jeff Johnson lowered the price target on Henry Schein (NASDAQ: HSIC) to $59.00 (from $66.00) while maintaining a Neutral rating. Organic revenue growth of +3.1% finished above pre-call estimates of +2.4%. However, organic growth in two of HSIC's higher-margin segments finished below expectations, contributing... More

Henry Schein (HSIC) Tops Q4 EPS by 1c, Revenues Miss; Offers FY19 EPS Guidance Below Consensus

February 20, 2019 7:03 AM EST

Henry Schein (NASDAQ: HSIC) reported Q4 EPS of $1.12, $0.01 better than the analyst estimate of $1.11. Revenue for the quarter came in at $3.38 billion versus the consensus estimate of $3.46 billion.

"This has been a historic year at Henry Schein as we further positioned the company to advance our 2018 to 2020 strategic plan. This included the creation of our Henry Schein One dental technology business, the spin-off of our animal health business into Covetrus (CVET) and restructuring efforts, which together are strategically positioning Henry Schein for continued success," said Stanley M. Bergman,... More